ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Lymphoblastoid If Test Shows Toxicity Not From Impurity, Investigator Says

August 8, 1980

Was Dr. Bunn Insensitive Or Just Efficient? FDA Imbroglio Points To Larger Problems

November 10, 1995

Mammography Had Limited Impact Among Swedish Women Age 40-69

July 27, 2012

Reinventing NCI: Natural Products Screen Closes; NCI Targets Drug Resistance

December 13, 1996

NCI’s Douglas Lowy and John Schiller Honored with National Medal

December 12, 2014

Three Genetics Pioneers Win Nobel Prize

October 11, 2002